IGMSIGM Biosciences, Inc.

Nasdaq igmbio.com


$ 9.36 $ 1.75 (22.88 %)    

Friday, 26-Apr-2024 15:59:39 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 9.4
$ 7.55
$ 0.00 x 0
$ 0.00 x 0
$ 7.55 - $ 9.47
$ 3.81 - $ 17.70
468,943
na
491.73M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-07-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 03-29-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-30-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-igm-biosciences-maintains-12-price-target

HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences (NASDAQ:IGMS) with a Neutral and maintains $12 price...

 rbc-capital-reiterates-outperform-on-igm-biosciences-maintains-21-price-target

RBC Capital analyst Brian Abrahams reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $21 price target.

 wedbush-reiterates-outperform-on-igm-biosciences-maintains-20-price-target

Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.

 igm-biosciences-q4-eps-101-beats-103-estimate-sales-65100k-miss-70000k-estimate

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.0...

 why-big-lots-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

 cymabay-therapeutics-contextlogic-snap-and-other-big-stocks-moving-higher-on-monday

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ...

 rbc-capitals-rating-upgrade-propels-igm-biosciences-into-immunology-limelight

IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Out...

 why-take-two-interactive-software-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter res...

 rbc-capital-upgrades-igm-biosciences-to-outperform-raises-price-target-to-21

RBC Capital analyst Brian Abrahams upgrades IGM Biosciences (NASDAQ:IGMS) from Sector Perform to Outperform and raises the p...

 sps-commerce-posts-upbeat-results-joins-masonite-international-impinj-and-other-big-stocks-moving-higher-on-friday

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ...

 morgan-stanley-reports-q4-results-joins-boeing-alcoa-and-other-big-stocks-moving-lower-on-tuesday

U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday.

 acuity-brands-posts-upbeat-earnings-joins-accolade-urban-outfitters-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.

 zimvie-agrees-to-sell-its-spine-business-joins-united-states-steel-pgt-innovations-and-other-big-stocks-moving-higher-on-monday

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.

 b-of-a-securities-downgrades-igm-biosciences-to-neutral-announces-8-price-target

B of A Securities analyst Geoff Meacham downgrades IGM Biosciences (NASDAQ:IGMS) from Buy to Neutral and announces $8 price ...

 hc-wainwright--co-downgrades-igm-biosciences-to-neutral-lowers-price-target-to-7

HC Wainwright & Co. analyst Robert Burns downgrades IGM Biosciences (NASDAQ:IGMS) from Buy to Neutral and lowers the pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION